JNJ ▼ -0.1% - Johnson & Johnson
$JNJ - New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
09-OCT-2026 07:01 AM ET
Share this post
More filings for $JNJ
JNJ ▲ +0.5% - Johnson & JohnsonOct 2, 2026JNJ ▲ +0.5% - Johnson & JohnsonOct 2, 2026JNJ ▼ -0.0% - Johnson & JohnsonSep 29, 2026JNJ ▲ +0.1% - Johnson & JohnsonSep 25, 2026JNJ ▲ +0.1% - Johnson & JohnsonSep 25, 2026JNJ ▲ +0.3% - Johnson & JohnsonSep 23, 2026
View full $JNJ filing history →💬 Comments
Loading comments…
Leave a comment